Uncategorized-EN

            The winners of the SPAEN Advocacy in Action Award 2020 have been announced! We congratulate them for their fantastic work:– V Care / SPANDAN, India– The Bone Cancer Research Trust, UK– The Polish Sarcoma and Melanoma Group Learn more about the winning projects, about all applications and about the…

In collaboration with the Fondazione IRCCS Istituto Nazionale dei Tumori, the Desmoid Foundation Italy is launching a survey to study the correlation between desmoid tumors and pregnancy. The results of this study will help to understand how desmoid tumors behave DURING pregnancy with the aim of improving the future of our patients who dream of…

European Commission Grants Lilly’s olaratumab (LARTRUVOTM), in Combination with Doxorubicin, Approval for the Treatment of Advanced Soft Tissue Sarcoma in Europe Olaratumab, in combination with doxorubicin, is the first front-line therapy approved in four decades for advanced soft tissue sarcoma in Europe JGDG study showed olaratumab, in combination with doxorubicin, offered a median 11.8-month increase…

The following table lists the results of some of the many clinical trials available worldwide for sarcoma, GIST or desmoid patients. For more information about some of the ongoing trials, click here. No Trial Name Agents Phase Status Results Sponsor 1 Study 62005 Imatinib in twodifferent dosings III Closed Results Study 62005 EORTC Note: The…

Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. HOW MANY patients participated? A total of 946 patients at 56 centers in 13 countries in Europe and Australia/New Zealand/Singapore took part…

Clinical studies are an essential step in the development of novel treatment methods for cancer and other diseases. They show researchers what works for the welfare of patients and what does not. In addition to safety and effectiveness they also determine whether the side effects of a new treatment are acceptable and, increasingly, what quality…

Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnershipPublished in ESMO Open, June 2022 Research in sarcomas has historically been the domain of scientists and clinicians attempting to understand the disease to develop effective treatments. This traditional approach of placing scientific…